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Abstract
Background: Patients with Enterobacter community-acquired pneumonia (EnCAP) were admitted to our intensive
care unit (ICU). Our primary aim was to describe them as few data are available on EnCAP. A comparison with CAP
due to common and typical bacteria was performed.
Methods: Baseline clinical, biological and radiographic characteristics, criteria for health-care-associated pneumonia
(HCAP) were compared between each case of EnCAP and thirty age-matched typical CAP cases. A univariate and
multivariate logistic regression analysis was performed to determine factors independently associated with ENCAP.
Their outcome was also compared.
Results: In comparison with CAP due to common bacteria, a lower leukocytosis and constant HCAP criteria were
associated with EnCAP. Empiric antibiotic therapy was less effective in EnCAP (20%) than in typical CAP (97%) (p <
0.01). A delay in the initiation of appropriate antibiotic therapy (3.3 ± 1.6 vs. 1.2 ± 0.6 days; p < 0.01) and an
increase in duration of mechanical ventilation (8.4 ± 5.2 vs. 4.0 ± 4.3 days; p = 0.01) and ICU stay were observed in
EnCAP patients.
Conclusions: EnCAP is a severe infection which is more consistent with HCAP than with typical CAP. This
retrospectively suggests that the application of HCAP guidelines should have improved EnCAP management.
Keywords: health-care-associated pneumonia community-acquired pneumonia, Enterobacter cloacae, Enterobacter
aerogenes, Gram-negative pneumonia
Background
Haemophilus influenzae, Klebsiella pneumoniae and
Escherichia coli are the most common aetiological agents
of community-acquired pneumonia (CAP) caused by
Gram-negative bacteria (GNB) [1,2]. Epidemiological
monitoring of CAP was started in 2002 in our intensive
care unit (ICU) and revealed an increase in occurrence of
severe Enterobacter CAP (EnCAP) from 2002 to 2005. No
specific reference to Enterobacter spp. is made in CAP stu-
dies [3,4], except for their low incidence in one recent
study [5]. The primary aim of this study was to describe
the characteristics of EnCAP, particularly to determine
their specific characteristics in comparison with CAP due
to common bacteria. This comparison included the pre-
s e n c eo fc r i t e r i af o rh e a l t h - c are-associated pneumonia
(HCAP) described since 2005, i.e. after completion of
EnCAP cases. HCAP refer to a new category of pneumo-
nia apparently developing in the community with the par-
ticularity to apply to patients who have recently interfaced
with the health care system [6,7]. Bacteria responsible for
HCAP can share the same susceptibility profile than hos-
pital-acquired bacteria. The awareness of these criteria
would then potentially improve the adequacy of empirical
treatment and the prognosis of the pneumonia. In our
study, we tested the hypothesis that it would have
improved the specific prognosis of EnCAP. * Correspondence: alexandre.boyer@chu-bordeaux.fr
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Study design
The study was performed in a 16-bed medical ICU (800
admissions/year) of a French teaching hospital (Bordeaux
University Hospital, Bordeaux, France). Prospective epi-
demiological monitoring, including all patients admitted
for CAP, was initiated on 01/01/2002. From that time
until 31/12/2004 (over 3 years), cases of microbiologi-
cally-confirmed EnCAP were gathered and described.
Each eligible case of EnCAP was then matched retrospec-
tively by an investigator blinded to the outcome or other
characteristics with three documented controls selected
from the prospective 3-year CAP cohort (excluding
Enterobacter and fungal pneumonia). Patients with a neu-
trophil count of <500/mm
3 and aspiration pneumonia
(defined by the development of a radiographically evident
infiltrate in patients with witnessed aspiration or at
increased risk for oropharyngeal aspiration) were also
excluded. The only matching criterion between cases and
controls was the same 5-year age group. According to
t h eC o m i t éd eP r o t e c t i o nd e sP e r s o n n e sS u d - O u e s te t
Outre Mer III (DC2010/44) and because no change was
done to our ICU’s usual practices, informed consent was
not required but patients and/or their proxies were
informed of the study’s purpose. The research was con-
ducted according to the Helsinki Declaration.
Data collection
During the study period, charts of patients admitted for
pneumonia were screened for comorbidities, predefined
clinical, radiological, microbiological, laboratory data and
therapeutic options. Hospital admission over the previous
3 years and, when available, time between the occurrence
of the first signs and admission was also registered.
Admission chest X-rays were pooled and then evaluated
retrospectively by two intensive care physicians blinded
to the presence of cases or controls. Simplified Acute
Physiology Score (SAPS II) [8], Sequential Organ Failure
Assessment (SOFA) [9] and sepsis classification [10]
were characterized 24 h after admission. Empirical and
definitive antibiotic choice and time between antibiotic
choice and admission were monitored for each patient.
Definitions
CAP was defined by the presence of symptoms of lower
respiratory tract infection along with two of the follow-
ing signs: fever (>38.3°C) or hypothermia (≤36°C), leuko-
cytosis (>10 × 10
9 cells/L) or leukopenia (5 × 10
8≤cells/
L≤ 4×1 0
9), new infiltrates on chest X-ray, in patients
not hospitalized. EnCAP was confirmed if Enterobacter
was isolated from sputum, bronchoalveolar lavage
(defined by an association of >25 leukocytes/mL, <25
epithelial cells on direct examination and a threshold for
bacterial positive cultures of 10
4 colony-forming units
(CFU)/mL), pleural fluid specimens, or blood cultures.
Sputum cultures were considered significant if the
microorganism was isolated in pure culture and if the
Gram-stained section showed >25 polymorphonuclear
leukocytes and <25 tracheo-bronchial epithelial cells
with a threshold for positive cultures of 10
7 CFU/mL.
HCAP criteria comprised one of the following criteria
[11,12]: (i) admission froman u r s i n gh o m eo ro t h e r
long-term nursing care facility; (ii) receiving outpatient
haemodialysis, peritoneal dialysis or infusion therapy
requiring regular visits to a hospital-based clinic; or (iii)
prior hospitalization within the preceding 12 months
[11,12]. Antimicrobial therapy given for pneumonia in
the 2 days before hospital admission was termed “prior
antibiotic therapy”. Antimicrobial therapy in the first
24 h was considered appropriate if it contained one or
more antimicrobial agent with in vitro activity against
the causative microorganism. Acute respiratory distress
syndrome (ARDS) was defined according to published
criteria [13].
Microbiological study
Investigation of pathogens in blood, fluid samples or spu-
tum was performed by standard microbiological proce-
dures. Identification to the species level was performed
with the API 20E (Biomérieux, Marcy l’Etoile, France) or
Phoenix system (BD Diagnostic, Le Pont-de-Claix,
France). Antibiotic susceptibility of the isolates was
determined by the disk diffusion method in MH agar
medium, according to French guidelines http://www.sfm.
asso.fr, or by the Phoenix system. The presence of an
extended-spectrum b-lactamase (ESBL)-producing strain
was detected by the double disk synergy test [14].
Statistics
All data were analysed using SAS version 9.2 software
(SAS Institute, Cary, NC, USA). EnCAP patients were
compared to patients with CAP due to common bacteria
for each characteristic (except for age which was the
matching criteria) by calculating odds ratio (OR) with 95%
CI using unconditional regression analysis. Explanatory
variables with a p value < 0.25 were included in the multi-
variable model using a stepwise descending method (back-
ward). In each model, the multicollinearity was
investigated between each variable: the variable that led to
the best predictive model was retained.
Results
During the 3-year study period, 134 patients were
admitted to our medical ICU from outside the hospital
setting for microbiologically-documented severe pneu-
monia. Ten patients (7.5%) had EnCAP.
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The general characteristics of the 10 patients as well as
their severity assessment, comorbidities and clinical
description are summarized in Table 1. All EnCAP
patients had at least one comorbidity. Four had cancer
(one chronic myeloid leukaemia, one colon cancer, one
pulmonary cancer and one breast cancer). All cases of
EnCAP were severe as shown by SAPS II score, the
occurrence of septic shock and the incidence of acute
renal failure. Alveolar (20%), interstitial (30%) or mixed
alveolo-interstitial (30%) aspects were observed in
EnCAP. Bilateral infiltrates were common (60%). Pleural
involvement was observed in 10% of cases of EnCAP.
EnCAP bacteriological findings
E. cloacae and E. aerogenes were confirmed in seven and
three cases, respectively. The microbiological diagnosis
was established by culture of sputum (4/10), bronchoal-
veolar lavage (3/10) or tracheobronchial aspirates in
ventilated patients (3/10) and by blood cultures in one
case. In one patient, E. cloacae was isolated (1.5 × 10
6
CFU/mL) in association with Moraxhella catarrhalis
(10
4 CFU/mL) from bronchoalveolar lavage. ESBL-pro-
ducing strains were isolated in four cases, including
ciprofloxacin resistance in two, gentamicine resistance
in one and amikacine resistance in another strain.
Univariate analysis of factors associated with CAP due to
Enterobacter sp compared with CAP due to common
bacteria
Each case of EnCAP was compared with three controls
so that 30 patients with common CAP were included. A
description of both groups and the results of univariate
analysis are shown in table 1 and 2 respectively. In the
Table 1 General characteristics and description of patients with community-acquired pneumonia due to Enterobacter
sp. compared to community-acquired-pneumonia due to common bacteria
Enterobacter CAP (n = 10) CAP (n = 30)
Age (years) 59.8 ± 20 64.3 ± 15.3
Male/female, % 80/20 64/36
SAPS II 44.9 ± 11.2 39 ± 13.3
SOFA/organ failure* 5.7 ± 3.3/1.2 ± 1.1 4.9 ± 3.3/0.9 ± 1.1
Comorbidities, n 1.7 ± 0.7 0.9 ± 0.8
COPD 41 2
cancer or haematological disease 4 6
diabetes mellitus 4 5
neurological 3 3
chronic heart failure 1 3
chronic renal failure 1 2
At least one comorbidity, % 100 60
Smoking history, n 3 11
Time between onset of symptoms and admission, days 3 ± 2 3 ± 2.7
Symptoms, n
T°>37.5°C 7 22
highest temperature, °C 39.6 ± 0.6 39.0 ± 1.0
chills 15
sweating 10
cough + sputum 4 16
Acute onset
$ /Progressive onset, n 4/6 19/11
Sepsis classification, n (%)
sepsis 2 (20) 10 (33)
severe sepsis 3 (30) 12 (40)
septic shock 5 (50) 8 (27)
Leukocytosis (G/L) 10.2 ± 4.8 15.1 ± 7.0
C-reactive protein (mg/dL) 207 ± 150 202 ± 132
Blood urea (mmol/L) 17.9 ± 12 10.3 ± 9.9
ARDS, n (%) 8 (80) 14 (47)
At least one HCAP criterion
¤, n 10 5
*Organ failure was defined by a SOFA score of 3 or higher for the evaluated parameter (example: a respiratory failure was considered if respiratory SOFA was 3
or 4);
$acute onset: <24 h;
¤cf. method.
CAP community-acquired pneumonia; SAPS Simplified acute physiology score; SOFA: sequential organ failure assessment; COPD: chronic obstructive pulmonary
disease; ARDS: acute respiratory distress syndrome; HCAP: Health-care associated pneumonia.
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Streptococcus pneumoniae (n = 8), methicillin-suscepti-
ble Staphylococcus aureus (n = 6), H. influenzae (n = 5),
Legionella pneumophilia and E. coli (n = 4), Streptococ-
cus viridans (n = 3), Chlamydia pneumoniae (n = 2),
Klebsiella oxytoca and K. pneumoniae (n = 1).
Clinical and biological findings
No difference was observed regarding age. By univariate
analysis, EnCAP patients tended to present with more
comorbidities (particularly diabetes and cancer or hae-
matological disease) while common CAP patients had a
more important leukocytosis. EnCAP patients also
tended to be more severe than CAP patients, as shown
by the incidence of acute renal failure and ARDS.
Radiographic findings
There was no significant difference in radiographic
findings
Criteria for HCAP
All patients in the EnCAP group were classified retro-
spectively as HCAP as prior hospitalization within the
preceding 12 months was observed in all cases. The
mean time between previous and current hospital
admission was 2.7 ± 3.9 months (range: 0.5-12 months).
All patients were living at home but one was considered
as a home care patient since he received intravenous
therapy at home. One patient had two HCAP criteria
(chronic renal failure requiring haemodialysis).
Multivariate analysis
Only a lower leukocytosis and the presence of at least
one criterion for HCAP were associated with EnCAP vs.
CAP due to common bacteria.
Antimicrobial therapy and sepsis outcome
Empirical antimicrobial therapy did not differ signifi-
cantly between the two groups (Table 3): a single antibio-
tic was used in 4/10 cases of EnCAP and 7/30 cases of
CAP (b-lactam drug in all cases but one, a macrolide for
the ultimate patient). A b-lactam drug combined with a
macrolide or fluoroquinolone was used in all other
patients in both groups. For EnCAP, empirical therapy
was appropriate in only 20% of patients compared to 97%
Table 2 Factors associated with community-acquired pneumonia due to Enterobacter sp. in comparison with
community-acquired pneumonia due to common bacteria








Male Sex 0.33 (0.06-1.81) 0.20 ...
SAPS II 1.04 (0.98-1.1) 0.21 ...
SOFA 1.08 (0.87-1.34) 0.5 ...




Time between onset of symptoms and admission 1 (0.74-1.34) 0.97 ...









Severe sepsis 1.25 (0.17-9.02)
Septic shock 3.13 (0.47-20.58)
Leukocytosis (G/L) 0.87 (0.76-1) 0.05 0.75 (0.59-0.96) 0.02
C-reactive protein (mg/dL) 1 (0.95-1.01) 0.92 ...
Blood urea (mmol/L) 1.06 (1-1.13) 0.07 ...
Radiographic findings ...
Predominant alveolar 1 0.41
Predominant interstitiel 1.85 (0.43-7.96)
ARDS 0.22 (0.04-1.21) 0.08 ...
Criteria for HCAP
No criterion 1 <0.01 1 <0.01
At least one criterion 45 (4.61-439.16) 244.6 (7.48-999.99)
$ Odds ratios were adjusted for age * Organ failure was defined by a SOFA score of 3 or higher for the evaluated parameter;
$acute onset: <24 h
HCAP: Health-care associated pneumonia; SAPS: simplified acute physiology score; SOFA: sequential organ failure assessment; ARDS: acute respiratory distress
syndrome.
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demonstrated by 2 additional days between the initiation
of empirical antimicrobial therapy at hospital admission
and subsequent definitive appropriate antimicrobial ther-
apy (p < 0.01). A trend in extended overall length of anti-
microbial therapy was observed for EnCAP compared to
CAP patients. After final antimicrobial therapy reassess-
ment, 8/10 patients received a combination of antibiotics
(including four with aminoglycosides) for EnCAP com-
pared to 19/30 CAP patients. The length of mechanical
ventilation and ICU stay were increased for EnCAP com-
pared to CAP, with only a trend towards a delayed reso-
lution of septic shock (as measured by the length of
vasoactive drug use) and an increase in hospital
mortality.
Discussion
This study provides new insights into non-nosocomial
Enterobacter pneumonia where previously published data
are scarce. This type of pneumonia is severe and seems
to develop in patients with serious comorbidities. Bouza
et al. [15] performed a retrospective study of 50 cases of
Enterobacter bacteraemia developing in the community
and reported several results that are in agreement with
our own conclusions: (i) a high prevalence of underlying
comorbidities; (ii) severe clinical presentation; and (iii)
high incidence of septic shock (30% in their study, 50% in
ours) [15]. Broughton et al. [16] reported an original case
of E. cloacae necrotizing CAP. In our study, a predomi-
nant alveolo-interstitial pattern was observed with no
cavitation or abscesses. This was reported previously
nearly 30 years ago in a reference radiographic study
[17]. No single clinical or radiographic finding other than
a lower leukocytosis was specific enough to consider this
pathogen in pneumonia.
However, these results should not conceal another
important study suggestion, that misclassifying pneumo-
nia occurring outside the hospital setting as CAP rather
than HCAP could have a number of consequences on
outcome. A recent editorial highlighted the fact that
HCAP criteria remained poorly identified, the majority of
physicians persisting in the prescription of regimens con-
sistent with CAP recommendations [18]. This should be
particularly crucial in patients with severe pneumonia
admitted to the ICU. In 2007, an extension of previously
proposed criteria was proposed [11] and validated more
recently [12]. Until and probably since 2005, patients pre-
senting with pneumonia outside the hospital setting
admitted to hospital or the ICU escaped these recom-
mendations [18-20]. We sought to retrospectively seek
for HCAP criteria because in our ICU we faced with an
increase in incidence of pneumonia due to an unusual
community-acquired bacterial species (i.e. Enterobacter
sp.) before 2005. Moreover we observed that Enterobac-
ter spp. were more frequent in epidemiological HCAP
studies [11,18,19] than in CAP studies [3-5]. Indeed,
patients received empirical antibiotic treatments designed
to take into account typical CAP bacteria, but these anti-
biotics failed to treat most EnCAP episodes (80%). A
delay in the improvement of EnCAP was observed in
comparison with adequately treated CAP. Should HCAP
criteria have been acknowledged, empirical antibiotics
with broader spectrum would have been used and an
improved prognosis would have probably occurred. In
Table 3 Antimicrobial therapy, other treatments and outcome of patients with community-acquired pneumonia due to
Enterobacter sp. compared to community-acquired-pneumonia due to common bacteria
Enterobacter CAP (n = 10) CAP
(n = 30)
p value
Prior antimicrobial treatment*, % 70 37 0.08
Prior antimicrobial treatment appropriateness
s, % 14 46 0.19
Empirical antimicrobial treatment appropriateness
$, % 20 97 < 0.01
Time between hospital admission
£ and definite appropriate antimicrobial treatment (days) 3.3 ± 1.6 1.2 ± 0.6 <0.01
Time between onset of empirical antimicrobial therapy and apyrexia (days)
¤ 5.6 ± 2.1 3.8 ± 2.4 0.06
Length of antimicrobial treatment (days) 11.8 ± 5.2 9.6 ± 3.8 0.16
Vasoactive or inotropic drug length of use (days)** 8 ± 3.9 4.8 ± 3.2 0.13
Dialysis, n (%) 3 (30) 3 (10) 0.14
Ventilation
¤¤, n (%) 10 (100) 18 (60) 0.96
Length of ventilation (days) 8.4 ± 5.2 4 ± 4.3 0.01
Length of ICU stay (days) 21 ± 15 11.9 ± 9.2 0.04
Hospital mortality, n (%) 3 (30) 5 (17) 0.37
Data are expressed as mean ± SD unless specified otherwise.
*Antibiotic started <24 h before ICU admission;
sprior antimicrobial treatment was defined as a treatment initiated in the 2 days preceding hospital admission;
$empirical antimicrobial treatment was initiated after hospital admission as soon as pneumonia was diagnosed;
£at admission for CAP;
¤apyrexia was defined as
temperature ≤37°C; **for five and eight patients respectively in EnCAP and CAP;
¤¤invasive or non-invasive ventilation.
SD: standard deviation; CAP: community-acquired pneumonia; ICU: intensive care unit.
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the retrospective diagnosis of HCAP was a history of pre-
vious hospitalization. The recent proposition of extension
to >1 year [11] confers the advantage of improving the
negative predictive value of HCAP criteria in order to
make physicians more confident about using antibiotics
with activity limited to purely community flora. Extend-
ing the interval beyond 1 year would reduce the positive
predictive value without further improving the negative
predictive value, and broad-spectrum antibiotic treat-
ment would then be used unnecessarily. Among the cri-
teria for HCAP, a history of previous hospitalization or
antibiotic treatment is less easy to retrieve than admis-
sion from a health-care facility, especially in the ICU
where patients often cannot be questioned. Our study
shows that history of previous hospitalization must be
investigated thoroughly in patients presenting with non-
nosocomial pneumonia, or HCAP will potentially be
wrongly classified as CAP.
The high proportion (40%) of ESBL-producing Entero-
bacter spp. in our study was significant. The emergence
of ESBL enterobacteriaceae (ESBLE) strains in the com-
munity has been described previously, particularly in
Europe [21]. Known risk factors include diabetes, prior
hospital admission and previous antibiotic use [22] which
corroborate our results. Of note, aminoglycosides remain
often effective against these strains. Whether ESBLE gas-
trointestinal carriage is due to selection by antibiotic
treatment used in the community, or to prolonged noso-
comial acquisition in the community, remains unclear.
Oral third-generation cephalosporins are commonly used
in outpatients in France. Third-generation cephalospor-
ins are known risk factors for ESBLE carriage [23]. How-
ever, in a more recent study, nosocomial acquisition of
ESBLE followed by prolonged digestive carriage prior to
community-acquired infection was strongly suggested by
genotypic analysis [24].
The small population size in our study is an important
limitation. Any conclusions drawn from this study should
be regarded with caution. Besides, one could argue that
BAL also recovered Moraxhella catarrhalis in a patient
from the EnCAP group. However, BAL is a highly specific
method and Enterobacter sp.g r e wt oah i g h e rt h r e s h o l d
than Moraxhella sp. (1.5 × 10
6 CFU/mL vs 10
4 CFU/mL).
Moreover the empiric antibiotic treatment of this patient
(i.e. coamoxiclav) covered Moraxhella sp. but not Entero-
bacter sp. explaining the delay in the improvement of clin-
ical signs of CAP. Statistical results excluding this case
were not modified. The study precludes any firm conclu-
sions about the relationship between the delay in appro-
priate antibiotic therapy and its influence on outcome.
The severity of the underlying illnesses could have played
an independent role and only multivariate analysis would
have provided a sounder insight into this complex
relationship. However, it is now accepted that any delay in
appropriate antibiotic treatment in patients with septic
shock is associated with a worse outcome [25]. The design
of our study does not answer the question as to whether
the worse outcome of EnCAP compared to common CAP
is due to antibiotic inappropriateness (i.e. noncompliance
with HCAP concept) or to Enterobacter itself. Only a com-
parison between Enterobacter HCAP and EnCAP could
answer this question. However, two studies have reported
the absence of specific findings with Enterobacter sp. com-
pared with other Gram-negative bacteria [1,17]. Therefore,
it suggests that only noncompliance with HCAP concept
was responsible for this worse outcome. Finally, previous
antibiotic treatment could not be assessed accurately in
our patients as it was a retrospective study. Some of the
patients in the EnCAP group could also have received
antibiotic treatment in the previous months. However, as
already suggested, this is not always easy to ascertain in
the real-life management of severe pneumonia.
Conclusions
In conclusion, this study shows that intensive care and
other physicians can be faced with severe EnCAP in
patients with comorbidities. The study is a plea for a
greater awareness of the HCAP criteria: to ignore them
may lead to inappropriate antibiotic treatment. HCAP
criteria, and particularly history of previous hospital
admission, should be systematically and thoroughly
investigated at the time of admission of such patients.
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